BTIG analyst Sung Ji Nam raised his price target on Thermo Fisher to $310 and kept his Buy rating after its announced $1.7B deal to buy Brammer Bio. The analyst sees "minimal" revenue and earnings impact from the purchase in the near term but sees the company "gaining valuable capabilities to support one of the fastest growing areas within the biopharma end market" as a result of the transaction. Sung Ji Nam concludes that the acquisition makes "financial sense" given Thermo Fisher's "successful foray" into the contract development and manufacturing organization, or CDMO, market.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here